LEE011 succinate

For research use only. Not for therapeutic Use.

  • CAT Number: I001444
  • CAS Number: 1374639-75-4
  • Molecular Formula: C27H36N8O5
  • Molecular Weight: 552.63
  • Purity: ≥95%
Inquiry Now

LEE011 succinate(Cat No.:I001444), also known as ribociclib, is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), crucial in regulating the cell cycle and promoting cancer cell proliferation. This compound is primarily investigated for its therapeutic potential in treating hormone receptor-positive breast cancer, particularly in combination with endocrine therapies. By inhibiting CDK4/6 activity, LEE011 succinate effectively halts tumor cell progression, leading to improved patient outcomes. Its oral bioavailability and favorable pharmacokinetic profile enhance its usability in clinical settings, positioning it as a valuable option in oncology treatment regimens.


Catalog Number I001444
CAS Number 1374639-75-4
Synonyms

(E)-7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)imino)-3,7-dihydro-2H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate

Molecular Formula C27H36N8O5
Purity ≥95%
Target CDK
Solubility 10 mM in DMSO
Storage Store at -20C
IC50 307 ± 68 nM (neuroblastoma-derived cell lines)
IUPAC Name butanedioic acid;7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide
InChI InChI=1S/C23H30N8O.C4H6O4/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30;5-3(6)1-2-4(7)8/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28);1-2H2,(H,5,6)(H,7,8)
InChIKey NHANOMFABJQAAH-UHFFFAOYSA-N
SMILES CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5.C(CC(=O)O)C(=O)O
Reference

<p style=/line-height:25px/>
<br>[1]. Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Oct 28.
Abstract
PURPOSE: Neuroblastoma is a pediatric cancer that continues to exact significant morbidity and mortality. Recently, a number of cell-cycle proteins, particularly those within the Cyclin D/CDK4/CDK6/RB network, have been shown to exert oncogenic roles in neuroblastoma, suggesting that their therapeutic exploitation might improve patient outcomes. Experimental Procedures: We evaluated the effect of dual CDK4/CDK6 inhibition on neuroblastoma viability using LEE011 (Novartis Oncology), a highly specific CDK4/6 inhibitor. RESULTS: Treatment with LEE011 significantly reduced proliferation in 12 of 17 human neuroblastoma-derived cell lines by inducing cytostasis at nanomolar concentrations (mean IC50 = 307 ± 68 nmol/L in sensitive lines). LEE011 caused cell-cycle arrest and cellular senescence that was attributed to dose-dependent decreases in phosphorylated RB and FOXM1, respectively. In addition, responsiveness of neuroblastoma xenografts to LEE011 translated to the in vivo setting in that there was a direct correlation of in vitro IC50 values with degree of subcutaneous xenograft growth delay. Although our data indicate that neuroblastomas sensitive to LEE011 were more likely to contain genomic amplification of MYCN (P = 0.01), the identification of additional clinically accessible biomarkers is of high importance. CONCLUSIONS: Taken together, our data show that LEE011 is active in a large subset of neuroblastoma cell line and xenograft models, and supports the clinical development of this CDK4/6 inhibitor as a therapy for patients with this disease. Clin Cancer Res; 19(22); 6173-82. ?2013 AACR.
</p>

Request a Quote